Mindbloom vs. Joyous: Comparing Ketamine Therapy Programs

Mindbloom vs. Joyous at a Glance

Choosing the best at home ketamine therapy requires understanding the different approaches providers take to patient care. This comparison covers the treatment philosophies, support models, and clinical evidence behind Mindbloom and Joyous to help you make an informed decision.

At a core level, Mindbloom delivers a clinician-supervised care model where ketamine is one component of a guided therapeutic process. Joyous delivers a low-cost daily microdosing subscription that relies primarily on asynchronous, app-based check-ins.

Both providers operate within established medical frameworks. Ketamine has been FDA-approved as an anesthetic since 1970 and has been on the World Health Organization's List of Essential Medicines since 1985.

Both companies prescribe ketamine off-label for mental health conditions. This is a widespread and legally accepted medical practice in the United States.⁸

How Mindbloom Works

Mindbloom is a guided at-home ketamine therapy provider offering structured programs of 6, 12, or 18 sessions. Ketamine is delivered as part of a complete care model that includes clinician consults, guide coaching, integration support, and community access.

The process begins with an initial clinical evaluation via telehealth to create a personalized treatment plan. During a session, you use either sublingual tablets or subcutaneous injectables while a peer treatment monitor, a friend or family member you choose, is required to be present.

Treatment frequency is personalized based on clinical guidance. Sessions may be more frequent initially to build therapeutic momentum, then adjusted based on your progress.

As of October 2026, Mindbloom has facilitated over 900,000 clinician-supervised sessions. It is also the only at-home ketamine provider offering subcutaneous administration in addition to sublingual tablets.

Mindbloom Pros

• Published evidence: Peer-reviewed outcomes data published on its own specific protocol.
• Administration options: Both sublingual tablets and subcutaneous injectables are available.
• High-touch support: Includes 1:1 coaching with a trained psychedelic integration specialist, unlimited Group Integration Circles, and unlimited guide messaging.
• Comprehensive tools: Access to the Mindbloom app with 10+ therapeutic programs, custom soundscapes, and a physical Bloombox toolkit.
• Value: Approximately 60% more affordable per session than traditional IV ketamine clinics.

Mindbloom Cons

• Upfront investment: Higher initial cost than a monthly microdosing subscription.
• Support requirement: A peer treatment monitor must be present during every session.
• Time commitment: Sessions require dedicated time and a post-session transition period, rather than acting as a background treatment.
• Availability: Not currently available in all 50 states.

Mindbloom Pricing and Programs

Mindbloom offers different program tiers, including a New Client 6-session program and Returning Client programs of 6, 12, or 18 sessions. Because the Mindbloom cost varies based on the selected program, prospective clients should check the company's website for current pricing. While Mindbloom does not currently accept insurance directly, HSA or FSA funds may often be used to cover treatment costs.

How Joyous Works

Joyous is an at-home ketamine provider that utilizes a daily low-dose model, often referred to as microdosing or psycholytic therapy. The medication is delivered via sublingual troches on a monthly subscription basis.

This approach is designed to provide consistent, mildly perceptual effects and generally aims for less pronounced dissociative intensity than session-based therapeutic dosing. The Joyous model begins with an online intake and a required video consult with a clinician.

You are prescribed low-dose troches, typically starting around 10 to 15mg. You report your daily mood through text-based check-ins, and clinicians titrate your dose accordingly. Support is primarily asynchronous and app-based, and Joyous positions itself as an affordable, accessible entry point into ketamine therapy.

Joyous Pros

• Low monthly cost: Joyous starts at $159 a month, or $129 a month with a three-month commitment (as of October 2026), including medication and app-based support.
• Daily routine: Dosing is designed to minimize disruption to daily functioning.
• No monitor needed: A peer treatment monitor is not required during administration.
• Accessibility: Provides a low barrier to entry for ongoing use.

Joyous Cons

• Lack of protocol data: No published peer-reviewed outcomes data evaluating its own specific model.
• Asynchronous support: After the initial video consult, care relies primarily on daily text-based check-ins rather than live coaching or group integration.
• Administration method: Joyous offers sublingual troches as its sole administration option.
• Long-term questions: Daily dosing raises questions about long-term use patterns that have not been extensively studied in peer-reviewed literature under this specific model.

Joyous Pricing and Subscription

The Joyous cost is structured as a monthly subscription. Joyous starts at $159 a month, or $129 a month with a three-month commitment (as of October 2026). This recurring fee covers the medication, daily text-based check-ins, and asynchronous clinician oversight via their app.

Mindbloom vs. Joyous Key Differences

Now that both models are outlined, it is helpful to compare them across the dimensions that matter most when choosing a provider. Each subsection below addresses a specific axis of comparison to help you evaluate your options.

Clinical Evidence and Published Research

Published outcomes data on a provider's own protocol means that peer-reviewed studies have evaluated outcomes specifically from that provider's clients. Those results describe the provider's own clients, rather than general ketamine research applied by association.

Mindbloom has published three peer-reviewed, real-world outcomes studies of at-home ketamine therapy, including Mathai et al. (2024), the largest published study of at-home ketamine therapy.¹ Mindbloom's peer-reviewed outcomes come from clients receiving the same clinician-and-guide care described below. Joyous references general ketamine literature but has not published peer-reviewed research evaluating outcomes from its own daily low-dose protocol.

Care Model and Support Structure

A care model encompasses the full system of clinical oversight, therapeutic support, and integration surrounding the medication itself.

• Mindbloom's approach: Every Mindbloom client works with a dedicated guide, a trained psychedelic integration specialist who helps them prepare for each session and turn what comes up into lasting change. Guides are hired with a coaching certification or 500+ hours of coaching experience with 50+ clients, complete Mindbloom's training protocol, and about 75% hold two or more certifications in areas like trauma healing or addiction recovery. Guides are part of a care team led by licensed clinicians, who handle evaluation, prescribing, and dosing, and guides share safety and progress updates with them. Programs also include unlimited guide-led Group Integration Circles.
• Joyous's approach: An online intake and a required video consult with a clinician, followed by daily text-based mood check-ins. Clinicians review those check-ins to titrate the low-dose troches. Support is primarily asynchronous and app-based, and a peer treatment monitor is not required.

The distinction lies between a session-based program with built-in coaching and integration and a daily-dosing subscription with clinician-reviewed check-ins. Different individuals may value different levels of support depending on their clinical needs.

Administration Methods and Dosing

Mindbloom offers two administration routes. You can choose sublingual tablets held between the cheek and gum, or subcutaneous injectables self-administered in the abdomen. Doses are sub-anesthetic and clinician-determined based on your individual clinical needs.

Joyous uses sublingual troches exclusively, administered daily at very low doses intended to be sub-perceptual or mildly perceptual. These two approaches represent fundamentally different treatment philosophies. One uses periodic therapeutic doses within a dedicated session, while the other uses daily low doses intended as background support.

Treatment Frequency and Scheduling

Mindbloom programs are built as 6, 12, or 18 sessions with personalized treatment frequency, and each session needs dedicated time plus a post-session transition. Joyous utilizes a daily model where the troche is taken once per day as part of a continuous regimen.

Mindbloom's model is session-based and time-bounded with a defined program arc. Joyous's model is continuous and open-ended, designed not to require dedicated session time.

Cost, Insurance, and Value

Mindbloom utilizes program-based pricing that varies by session count, while Joyous charges a flat monthly subscription fee. Neither provider currently accepts insurance directly, though HSA or FSA funds may be eligible for both.

When evaluating cost, consider what is included in the price. Mindbloom's price encompasses clinician consults, guide coaching, integration circles, the Bloombox, and app access. Joyous's price covers medication, text-based check-ins, and clinician oversight.

Safety Protocols and Clinical Screening

Safety protocols in at-home ketamine therapy encompass screening, monitoring, in-session safety measures, and escalation procedures. Safety is a function of clinical supervision, screening, and structured protocols, not dose size alone.⁹ Ketamine can temporarily increase blood pressure and heart rate during a session.¹⁰ Individuals with uncontrolled hypertension may not be appropriate candidates, which is why cardiovascular screening is a critical part of the intake process.⁹

• Mindbloom's screening: Conducts clinical screening via telehealth consults to evaluate medical history and contraindications, and requires a peer treatment monitor to be present during every session.
• Joyous's screening: Conducts an online intake and a required video consult, then monitors patients via daily text check-ins, without requiring an in-session support person.

Both providers include medical screening to evaluate appropriateness for care. The models differ primarily in the depth and frequency of clinical touchpoints and their specific in-session safety requirements.

Mindbloom Outcomes From Published Research

Mindbloom's three studies, two in the Journal of Affective Disorders and a 2026 study of subcutaneous ketamine in the Journal of Medical Internet Research, all evaluated Mindbloom clients using validated clinical instruments. Direct comparisons across treatment modalities should be interpreted with caution due to differences in study design, patient populations, and outcome measures. These results build on decades of clinical research, though individual results may vary.

• Depression: In a peer-reviewed study of 11,441 Mindbloom clients using sublingual tablets, 56.4% met criteria for response and 28.1% reached remission.¹ Mindbloom's sublingual depression response rate (56.4%) is within the range reported in selected SSRI antidepressant studies⁴ and comparable to those reported in selected IV ketamine studies.⁶ In an earlier peer-reviewed study of 1,247 Mindbloom clients, 89% reported improvement in their symptoms after four sessions.⁷
• Anxiety: Among the 7,776 patients in that study with baseline anxiety scores, 56.1% met criteria for anxiety response and 28.8% reached remission.¹ That response rate is about 19% higher than the rate reported for CBT for generalized anxiety (56.1% vs. 47%), though the studies involved separate populations.¹²
• PTSD: In a peer-reviewed study of at-home subcutaneous ketamine (Parks et al., 2026), 76.7% of Mindbloom clients with PTSD met response criteria and 56.7% reached remission by the end of the six-session course, and 84.6% saw clinically meaningful improvement.³ Mindbloom's PTSD response and remission (76.7% and 56.7% by the end of the six-session course) are comparable to or slightly exceeding the rates reported for intensive trauma therapy (about 72–76% response and about 54% loss of diagnosis), reached in about six sessions instead of a three-to-four-month course, though the comparator studies used intensive-format veteran and military cohorts.¹³ ¹⁴
• Sleep: In a preprint analysis of 13,963 Mindbloom clients, those who completed six sessions had a 77% response rate and an average 49% reduction in sleep disturbance severity.¹¹
• Safety: In Mindbloom's published outcomes data, side effects were reported in approximately 4–5% of participants, with serious adverse events in fewer than 0.1% of participants and 0.4% discontinuing due to adverse events.¹

Should You Choose Mindbloom or Joyous?

Deciding between these two providers depends on your treatment goals, budget, and preferred level of clinical support. Both are clinician-supervised, so the main differences are dosing cadence, session structure, and how much live support you want.

Mindbloom may be a better fit if:

• You want a clinically managed therapeutic program with defined sessions and a clear arc.
• You value 1:1 coaching and group integration support to help sustain progress.
• You want a provider with published peer-reviewed outcomes data on its own protocol.
• You are interested in subcutaneous administration for more consistent dosing.
• You prefer a high-touch care model with clinical oversight throughout the process.

Joyous may be a better fit if:

• You want a low, flat monthly cost.
• You prefer a daily routine that does not require dedicated session time.
• You are comfortable with asynchronous app-based support rather than live coaching.
• You want a gentle, sub-perceptual approach with less emphasis on the more immersive dissociative experience sometimes associated with session-based dosing.

If you are ready to explore guided at-home ketamine therapy backed by published research and a comprehensive care model, you can begin your assessment with Mindbloom.

Safety and Medical Disclaimer

IMPORTANT SAFETY INFORMATION
‍Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary.Full safety information: www.mindbloom.com/safety-information‍

‍OFF-LABEL USE DISCLOSURE
‍Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.